Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately ...

Bexobrutideg could win FDA approval if a mid-stage trial shows the drug does what Nurix leaders think it can do against ...

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton ...

My husband was diagnosed with chronic lymphocytic leukemia (CLL) in 2010 and remained in stage 2 with no effects until 2022. In the interim, he was also diagnosed with atrial fibrillation and is ...

Abcuro, Inc., a late-stage clinical biotechnology company developing potential first-in-class immunotherapies for the benefit of people living with debilitating and progressive rare autoimmune ...

Herein, we systematically investigated the value of PB MRD assessments in patients with CLL who achieved a CR and PR, and analyzed the role of MRD in patients with a PR who presented with residual ...

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...

Gastroenterologists and pathologists are recognizing nonbloody watery diarrhea owing to 'microscopic colitis' with increasing frequency; this disease is therefore an important clinical and ...

Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide Four weeks after ...

Of all leukemias, chronic lymphocytic leukemia (CLL) shows the highest variability in its clinical presentation and course. CLL can present as an aggressive and life threatening leukemia or as an ...

Lymphocytic and collagenous colitis are forms of microscopic colitis that can be caused by drugs. After re-exposure to a causative medication, such as entacapone, recurrence can be more acute and ...

In what was once an incurable cancer — chronic lymphocytic leukemia — scientists are seeing remissions that could last for decades. November 2013 marked the start of Sonia Dolinger’s ...